MC-Val-Cit-PAB-MMAF (Synonyms: Vc-MMAF) |
| Catalog No.GC61035 |
MC-Val-Cit-PAB-MMAF (Vc-MMAF) est un conjugué médicament-lieur pour l'ADC utilisant l'inhibiteur de la tubuline, MMAF, lié via la cathepsine clivable MC-Val-Cit-PAB. MC-Val-Cit-PAB-MMAF présente une activité antitumorale.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 863971-17-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
MC-Val-Cit-PAB-MMAF is a drug-linker conjugate for ADC with antitumor activity by using the tubulin inhibitor, MMAF, linked via cathepsin cleavable MC-Val-Cit-PAB.
[1]. Cheng X, et al. MORAb-202, an Antibody-Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor Activity. Mol Cancer Ther. 2018 Dec;17(12):2665-2675.
Average Rating: 5 (Based on Reviews and 36 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *